Lurbinectedin is a drug used in the treatment of advanced solid tumors and small cell lung cancer (SCLC). According to Drug Patent Watch [1], the drug was approved by the FDA in June 2020 for the treatment of SCLC. However, the success rate of Lurbinectedin treatment varies depending on the type and stage of cancer.

A study published in the Journal of Clinical Pharmacology [2] evaluated the efficacy of Lurbinectedin in patients with advanced solid tumors. The study found that Lurbinectedin demonstrated a favorable safety profile and antitumor activity in patients with advanced solid tumors. Another study published in the Journal of Clinical Oncology [3] evaluated the efficacy of Lurbinectedin in patients with SCLC. The study found that Lurbinectedin demonstrated promising antitumor activity in patients with SCLC who had previously received platinum-based chemotherapy.

In summary, the success rate of Lurbinectedin treatment varies depending on the type and stage of cancer. Lurbinectedin has demonstrated antitumor activity in patients with advanced solid tumors and SCLC. However, further studies are needed to determine the long-term efficacy and safety of Lurbinectedin treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.14464